Literature DB >> 20405154

The negative-balance isolated pelvic perfusion method using ultrahigh-dose cisplatin for invasive bladder cancer with poor risk.

Ryoji Kimata1, Yukihiro Kondo, Kaoru Nemoto, Satoru Murata, Tatsuo Kumazaki.   

Abstract

BACKGROUND: Our aim was to evaluate the clinical significance of the negative-balance isolated pelvic perfusion (NIPP) method using ultrahigh-dose cisplatin (CDDP) for ten cases of invasive bladder cancer with poor risk such as high-grade cancer, advanced clinical stage, or appearance of hydronephrosis.
METHODS: A CDDP dosage of 200-300 mg/body was used under the NIPP method. To confirm safety and efficacy, peripheral blood, pelvic arterial blood, pelvic venous blood, and urine were collected for sampling of the platinum (Pt) concentrations. These samples were investigated and compared with those following previous intraarterial chemotherapy sessions.
RESULTS: The Pt concentrations in pelvic blood under intraarterial chemotherapy and NIPP were 5.97 ± 2.06 and 24.15 ± 4.61 μg/ml, respectively. By contrast, the Pt concentration in peripheral blood under NIPP was half the level under conventional intraarterial chemotherapy. No severe adverse events were found in terms of gastrointestinal and hematological toxicity, but renal function was impaired in some cases. Pathological or surgical complete response (CR) was achieved in five of ten cases (50%) in spite of the group being poor risk, and bladder preservation was possible in all the CR cases. Patients with CR experienced survival in all terms of observation.
CONCLUSIONS: The NIPP method was able to deliver high levels of CDDP concentration in pelvis cavity without severe adverse events. The NIPP method makes it possible to achieve CR for the patients with invasive bladder cancer with poor risk who rejected cystectomy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20405154     DOI: 10.1007/s10147-010-0079-0

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  17 in total

1.  Treatment of malignant pelvic tumors by extracorporeal perfusion with chemotherapeutic agents.

Authors:  W G AUSTEN; A P MONACO; G S RICHARDSON; W H BAKER; R S SHAW; J W RAKER
Journal:  N Engl J Med       Date:  1959-11-19       Impact factor: 91.245

2.  Health related quality of life after orthotopic neobladder construction and its comparison with normative values in the Japanese population.

Authors:  Tatsuaki Yoneda; Hiroyuki Adachi; Shinji Urakami; Hirofumi Kishi; Kazushi Shigeno; Hiroaki Shiina; Mikio Igawa
Journal:  J Urol       Date:  2005-11       Impact factor: 7.450

3.  Neoadjuvant high-dose intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration in patients with stages IIIa-IVa cervical cancer.

Authors:  Satoru Motoyama; Shinya Hamana; Yonson Ku; Jovelle B Laoag-Fernandez; Masashi Deguchi; Shigeki Yoshida; Masahiro Tominaga; Takeshi Iwasaki; Noriyuki Ohara; Takeshi Maruo
Journal:  Gynecol Oncol       Date:  2004-12       Impact factor: 5.482

4.  Reduction of drug leakage by negative-balance isolated pelvic perfusion: correlation between leakage and in-out flow rate in a pig model.

Authors:  Satoru Murata; Hiroyuki Tajima; Gen-ichi Kusakai; Tatsuo Kumazaki; Yutaka Abe; Shiro Onozawa; Yasushige Komada; Yukihiro Kondo; Ryoji Kimata; Seiichiro Himeno; Mitsuo Satake
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

Review 5.  Trimodality treatment and selective organ preservation for bladder cancer.

Authors:  Claus Rödel; Christian Weiss; Rolf Sauer
Journal:  J Clin Oncol       Date:  2006-12-10       Impact factor: 44.544

6.  Effect of adjuvant transarterial infusion of anticancer agents after transurethral resection in patients with pT2a muscle invasive transitional cell carcinoma of the bladder: five and ten-year outcome.

Authors:  Hiroyuki Shimizu; Taiji Nishimura; Go Kimura; Ichiro Matsuzawa; Yukihiro Kondo
Journal:  J Nippon Med Sch       Date:  2004-08       Impact factor: 0.920

7.  Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum.

Authors:  Harold J Wanebo; Michael DiSiena; Giovanni Begossi; James Belliveau; Eric Gustafson
Journal:  Ann Surg Oncol       Date:  2007-12-22       Impact factor: 5.344

Review 8.  Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer?

Authors:  M Kuczyk; Levent Turkeri; Peter Hammerer; Vincent Ravery
Journal:  Eur Urol       Date:  2003-07       Impact factor: 20.096

9.  Effect of combined therapy using balloon-occluded arterial infusion of cisplatin and hemodialysis with concurrent radiation for locally invasive bladder cancer.

Authors:  Haruhito Azuma; Yatsugu Kotake; Kazuhiro Yamamoto; Takeshi Sakamoto; Satoshi Kiyama; Takanobu Ubai; Teruo Inamoto; Kiyoshi Takahara; Mitsuru Matsuki; Naoki Segawa; Nobuhisa Shibahara; Yoji Katsuoka
Journal:  Am J Clin Oncol       Date:  2008-02       Impact factor: 2.339

10.  Large volume loading to prevent cisplatin-induced nephrotoxicity during negative-balance isolated pelvic perfusion.

Authors:  Keiko Nakazato; Chol Kim; Katsuyuki Terajima; Satoru Murata; Hitoshi Fujitani; Kazuhiro Nakanishi; Hiroyuki Tajima; Tatsuo Kumazaki; Atsuhiro Sakamoto
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-15       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.